PainReform Ltd. (NASDAQ:PRFX) Sees Significant Increase in Short Interest

PainReform Ltd. (NASDAQ:PRFX) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totaling 127,699 shares, a growth of 122.3% from the June 15th total of 57,440 shares. Currently, 22.4% of the company’s shares are short sold. Based on an average daily volume of 2,063,956 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of PainReform in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

PainReform Trading Down 7.1%

Shares of PainReform stock opened at $1.18 on Friday. The business has a 50-day moving average price of $1.57 and a two-hundred day moving average price of $2.49. PainReform has a 1-year low of $1.16 and a 1-year high of $17.95. The company has a market cap of $1.03 million, a P/E ratio of -0.00 and a beta of 1.05.

PainReform (NASDAQ:PRFX) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($1.01) earnings per share (EPS) for the quarter.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.